38,500 Shares in Adaptive Biotechnologies Corporation $ADPT Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new stake in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 38,500 shares of the company’s stock, valued at approximately $826,000.

Several other institutional investors also recently bought and sold shares of ADPT. Caitong International Asset Management Co. Ltd purchased a new stake in Adaptive Biotechnologies during the fourth quarter worth about $28,000. EverSource Wealth Advisors LLC boosted its stake in shares of Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares during the period. KBC Group NV purchased a new position in shares of Adaptive Biotechnologies in the first quarter valued at approximately $45,000. Assetmark Inc. grew its holdings in shares of Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after purchasing an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new position in shares of Adaptive Biotechnologies in the fourth quarter valued at approximately $51,000. 99.17% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ADPT. Guggenheim increased their target price on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. JPMorgan Chase & Co. dropped their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. TD Cowen increased their price objective on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Finally, Morgan Stanley lifted their target price on Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.42.

Adaptive Biotechnologies Trading Down 0.8%

NASDAQ:ADPT opened at $24.56 on Wednesday. Adaptive Biotechnologies Corporation has a 1 year low of $12.00 and a 1 year high of $26.16. The stock has a market cap of $3.92 billion, a P/E ratio of -59.90 and a beta of 2.08. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. The stock has a 50-day simple moving average of $21.58 and a 200-day simple moving average of $17.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The business had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.Adaptive Biotechnologies’s revenue was up 21.5% on a year-over-year basis. During the same period last year, the business posted ($0.17) EPS. As a group, analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current fiscal year.

Insider Activity at Adaptive Biotechnologies

In other news, insider Harlan S. Robins sold 492,400 shares of the company’s stock in a transaction on Tuesday, July 21st. The shares were sold at an average price of $21.89, for a total value of $10,778,636.00. Following the completion of the transaction, the insider owned 812,058 shares in the company, valued at approximately $17,775,949.62. This represents a 37.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Susan Bobulsky sold 11,000 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $18.00, for a total transaction of $198,000.00. Following the completion of the transaction, the insider owned 416,775 shares of the company’s stock, valued at $7,501,950. This represents a 2.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,306,971 shares of company stock valued at $27,894,120. Company insiders own 5.70% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.